A multicenter, randomized, double-blind, placebo-controlled phase III study of apatinib or placebo plus gefitinib as first-line treatment in patients with EGFR-mutant advanced non-small cell lung cancer (NSCLC)

被引：1

作者：

Zhao, Hongyun

Zhang, Zhonghan

Luo, Fan

Ma, Yuxiang

Fang, Wenfeng

Yang, Yunpeng

Zhang, Yang

Huang, Yan

Zhang, Li

机构：

[1] Sun Yat Sen Univ, Caner Ctr, State Key Lab Oncol South China, Guangzhou, Guangdong, Peoples R China

[2] Sun Yat Sen Univ, Canc Ctr, Guangzhou, Guangdong, Peoples R China

[3] Sun Yat Sen Univ, Collaborat Innovat Ctr Canc Med, State Key Lab Oncol South China, Canc Ctr, Guangzhou, Guangdong, Peoples R China

来源：

关键词：

D O I：

10.1200/JCO.2018.36.15_suppl.TPS9116

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

TPS9116

引用

页数：2